About nxera pharma co ltd - SOLTF
Nxera Pharma Co., Ltd. is a technology powered biopharma company focused on specialty medicines in Japan and globally. The company engages in activities from discovery through to late clinical stage and commercialization, internally and in partnership with global pharma and biotech companies. It focuses on some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders, and rare diseases, and leverages the power of its GPCR targeted structure based drug discovery NxWave platform to provide a source of best- or first-in-class medicines. The company was founded by Shinichi Tamura and Takaya Nakamura on June 22, 1990 and is headquartered in Tokyo, Japan.
SOLTF At a Glance
Nxera Pharma Co., Ltd.
Midtown East
Tokyo, Tokyo 107-0052
| Phone | 81-3-5962-5718 | Revenue | 190.34M | |
| Industry | Pharmaceuticals: Major | Net Income | -31,935,067.71 | |
| Sector | Health Technology | 2024 Sales Growth | 109.649% | |
| Fiscal Year-end | 12 / 2025 | Employees | 374 | |
| View SEC Filings |
SOLTF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.144 |
| Price to Book Ratio | 1.375 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -87.829 |
| Enterprise Value to Sales | 4.203 |
| Total Debt to Enterprise Value | 0.54 |
SOLTF Efficiency
| Revenue/Employee | 508,920.952 |
| Income Per Employee | -85,387.882 |
| Receivables Turnover | 2.638 |
| Total Asset Turnover | 0.183 |
SOLTF Liquidity
| Current Ratio | 3.701 |
| Quick Ratio | 3.136 |
| Cash Ratio | 2.316 |
SOLTF Profitability
| Gross Margin | 62.868 |
| Operating Margin | -18.602 |
| Pretax Margin | -16.168 |
| Net Margin | -16.778 |
| Return on Assets | -3.072 |
| Return on Equity | -7.02 |
| Return on Total Capital | -3.679 |
| Return on Invested Capital | -3.596 |
SOLTF Capital Structure
| Total Debt to Total Equity | 99.098 |
| Total Debt to Total Capital | 49.773 |
| Total Debt to Total Assets | 44.819 |
| Long-Term Debt to Equity | 89.334 |
| Long-Term Debt to Total Capital | 44.869 |